Back to top
more

LeMaitre Vascular (LMAT)

(Delayed Data from NSDQ)

$65.46 USD

65.46
117,291

+2.47 (3.92%)

Updated Apr 26, 2024 04:00 PM ET

After-Market: $65.45 -0.01 (-0.02%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

1-Strong Buy of 5 1        

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value D Growth D Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 44% (140 out of 252)

Industry: Medical - Products

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

AtriCure's (ATRC) cryoSPHERE+ Probe to Aid in Pain Management

by Zacks Equity Research

AtriCure (ATRC) unveils its cryoSPHERE+ cryoablation probe, which is intended to reduce freeze times and aid in postoperative pain management.

Here's Why You Should Retain Medtronic (MDT) Stock for Now

by Zacks Equity Research

Investors continue to be optimistic about Medtronic (MDT) due to the strength of its Neurosurgery and Cardiovascular portfolios.

Here's Why You Should Hold BD (BDX) Stock in Your Portfolio

by Zacks Equity Research

BD's (BDX) slew of product launches and strategic deals raises optimism about the stock.

Baxter's (BAX) New Injectables Aid Its Pharmaceutical Portfolio

by Zacks Equity Research

Baxter (BAX) unveils its five injectable products, which strengthen its emphasis on unique products and expand the pharmaceutical portfolio of the business in important therapeutic areas.

Here's Why You Should Add DaVita (DVA) to Your Portfolio

by Zacks Equity Research

DaVita's (DVA) strength in its kidney care raises optimism about the stock.

Reasons to Hold Baxter International (BAX) in Your Portfolio

by Zacks Equity Research

Baxter International's (BAX) robust growth across all geographies, along with transformational initiatives, raises optimism.

Why You Should Add Ensign Group (ENSG) to Your Portfolio Now

by Zacks Equity Research

Ensign Group (ENSG) remains well-poised for growth on sustained top-line growth, a growing healthcare portfolio and solid operating cash flows.

Glaukos (GKOS) Hits 52-Week High: What's Driving the Stock?

by Zacks Equity Research

Investors are optimistic about Glaukos' (GKOS) strength in its flagship iStent.

BD's (BDX) Latest Product to Offer Wider Access to Researchers

by Zacks Equity Research

The latest worldwide commercial availability of BD's (BDX) cell sorters is set to expand researchers' capabilities to transform research and cell-based therapeutic development across numerous fields.

Here's Why Investors Should Hold Teladoc (TDOC) Stock Now

by Zacks Equity Research

Teladoc's (TDOC) Integrated Care business is expected to gain from margin expansion and improving chronic care program enrollment.

Compelling Reasons to Hold on to UnitedHealth Group (UNH) Stock

by Zacks Equity Research

UnitedHealth Group (UNH) remains well-poised for growth on the back of improved premiums, acquisitions and partnerships, an in-demand telehealth services suite and solid cash-generating abilities.

New Strong Buy Stocks for March 21st

by Zacks Equity Research

ANF, HENKY, PRLB, LMAT and GATX have been added to the Zacks Rank #1 (Strong Buy) List on March 21, 2023.

Encompass Health (EHC) Up 42% in a Year: What Lies Ahead?

by Zacks Equity Research

Encompass Health (EHC) remains well-poised for growth on the back of sustained top-line growth, an expanding healthcare facility portfolio and robust cash-generating abilities.

Best Momentum Stocks to Buy for March 13th

by Zacks Equity Research

ANF, LMAT and CRH made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on March 13, 2024.

New Strong Buy Stocks for March 13th

by Zacks Equity Research

SBSI, EBMT, LMAT, ANF and FHI have been added to the Zacks Rank #1 (Strong Buy) List on March 13, 2024.

Best Momentum Stocks to Buy for March 7th

by Zacks Equity Research

TOL, WILYY and LMAT made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on March 7, 2023.

Ensign Group (ENSG) Buys Nursing Units, Boosts U.S. Footprint

by Zacks Equity Research

Ensign Group (ENSG) acquires two skilled nursing facilities in Colorado and one similar facility in Kansas to better serve the regions' patients and grow its healthcare portfolio.

LeMaitre Vascular (LMAT) is a Great Momentum Stock: Should You Buy?

by Zacks Equity Research

Does LeMaitre Vascular (LMAT) have what it takes to be a top stock pick for momentum investors? Let's find out.

Best Momentum Stocks to Buy for March 5th

by Zacks Equity Research

LMAT, SPXC and BBVA made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on March 5, 2023.

LeMaitre (LMAT) Upgraded to Buy: What Does It Mean for the Stock?

by Zacks Equity Research

LeMaitre (LMAT) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

MDT vs. LMAT: Which Stock Should Value Investors Buy Now?

by Zacks Equity Research

MDT vs. LMAT: Which Stock Is the Better Value Option?

LeMaitre Vascular (LMAT) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

by Zacks Equity Research

LeMaitre (LMAT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

SurModics (SRDX) Reports Break-Even Earnings for Q1

by Zacks Equity Research

SurModics (SRDX) delivered earnings and revenue surprises of 100% and 3.23%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

ESLOY or LMAT: Which Is the Better Value Stock Right Now?

by Zacks Equity Research

ESLOY vs. LMAT: Which Stock Is the Better Value Option?

How Much Upside is Left in LeMaitre (LMAT)? Wall Street Analysts Think 25.24%

by Zacks Equity Research

The consensus price target hints at a 25.2% upside potential for LeMaitre (LMAT). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.